HIV AND HEPATITIS POLICY INSTITUTE for HIV AND HEPATITIS POLICY INSTITUTE
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS MCDANIELS New | — |
| CARL SCHMID New | — |
Health Issues HCR
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS MCDANIELS New | — |
| CARL SCHMID New | — |
Insurance INS
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS MCDANIELS New | — |
| CARL SCHMID New | — |
Medicare/Medicaid MMM
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS MCDANIELS New | — |
| CARL SCHMID New | — |
Pharmacy PHA
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS MCDANIELS New | — |
| CARL SCHMID New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.